Patents by Inventor Guozhu XIE

Guozhu XIE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for immunotherapy of NPM1c-positive cancer
    Patent number: 11896619
    Abstract: The present disclosure relates to compounds (e.g., antibodies, antigen-binding fragments thereof, bispecific molecules, or chimeric antigen receptor polypeptides) that bind to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: February 13, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Jianzhu Chen, Guozhu Xie
  • METHODS FOR GENERATING ENGINEERED MEMORY-LIKE NK CELLS AND COMPOSITIONS THEREOF
    Publication number: 20230149460
    Abstract: The present disclosure relates to cytokine-induced memory-like NK cells expressing a chimeric antigen receptor polypeptide that binds to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: March 10, 2021
    Publication date: May 18, 2023
    Applicants: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.
    Inventors: Jianzhu Chen, Jerome Ritz, Rizwan Romee, Han Dong, Guozhu Xie, James Dongjoo Ham
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
    Publication number: 20210283178
    Abstract: The present disclosure relates to compounds (e.g., antibodies, antigen-binding fragments thereof, bispecific molecules, or chimeric antigen receptor polypeptides) that bind to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: January 8, 2021
    Publication date: September 16, 2021
    Inventors: Jianzhu CHEN, Guozhu XIE